[{"address1": "321 Arsenal Street", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "339 217 0161", "website": "https://www.iteostherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 173, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michel  Detheux Ph.D.", "age": 58, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 1120393, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew A. Call M.B.A.", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 725481, "exercisedValue": 0, "unexercisedValue": 1074044}, {"maxAge": 1, "name": "Dr. David  Feltquate M.D., Ph.D.", "title": "Chief Medical Officer", "fiscalYear": 2024, "totalPay": 774444, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Gall", "age": 47, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 648001, "exercisedValue": 0, "unexercisedValue": 1259823}, {"maxAge": 1, "name": "Dr. Yvonne  McGrath Ph.D.", "age": 50, "title": "Chief Scientific Officer", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Adi  Osovsky", "title": "Executive Vice President of Legal", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philippe  Brantegem", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 10.15, "open": 10.14, "dayLow": 10.15, "dayHigh": 10.15, "regularMarketPreviousClose": 10.15, "regularMarketOpen": 10.14, "regularMarketDayLow": 10.15, "regularMarketDayHigh": 10.15, "payoutRatio": 0.0, "beta": 1.493, "forwardPE": -1.7350427, "volume": 10981273, "regularMarketVolume": 10981273, "averageVolume": 1316457, "averageVolume10days": 2068440, "averageDailyVolume10Day": 2068440, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 448684800, "fiftyTwoWeekLow": 4.8, "fiftyTwoWeekHigh": 17.63, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 10.1353, "twoHundredDayAverage": 8.290475, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -61617212, "profitMargins": 0.0, "floatShares": 33237155, "sharesOutstanding": 44205400, "sharesShort": 2061672, "sharesShortPriorMonth": 3069614, "sharesShortPreviousMonthDate": 1752537600, "dateShortInterest": 1755216000, "sharesPercentSharesOut": 0.0466, "heldPercentInsiders": 0.00983, "heldPercentInstitutions": 0.90282995, "shortRatio": 1.34, "shortPercentOfFloat": 0.057800002, "impliedSharesOutstanding": 44205400, "bookValue": 12.903, "priceToBook": 0.78663874, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -202411008, "trailingEps": -4.73, "forwardEps": -5.85, "enterpriseToEbitda": 0.305, "52WeekChange": -0.3907563, "SandP52WeekChange": 0.16844666, "quoteType": "EQUITY", "currentPrice": 10.15, "targetHighPrice": 11.0, "targetLowPrice": 10.0, "targetMeanPrice": 10.3, "targetMedianPrice": 10.1, "recommendationKey": "none", "numberOfAnalystOpinions": 4, "totalCash": 515430016, "totalCashPerShare": 11.66, "ebitda": -202050000, "totalDebt": 5128000, "quickRatio": 7.371, "currentRatio": 7.528, "totalRevenue": 0, "debtToEquity": 1.038, "revenuePerShare": 0.0, "returnOnAssets": -0.18486, "returnOnEquity": -0.34969002, "grossProfits": 0, "freeCashflow": -22141250, "operatingCashflow": -108064000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ITOS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 0.0, "regularMarketPrice": 10.15, "regularMarketChange": 0.0, "regularMarketDayRange": "10.15 - 10.15", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1316457, "fiftyTwoWeekLowChange": 5.3499994, "fiftyTwoWeekLowChangePercent": 1.1145831, "fiftyTwoWeekRange": "4.8 - 17.63", "fiftyTwoWeekHighChange": -7.4799995, "fiftyTwoWeekHighChangePercent": -0.4242768, "fiftyTwoWeekChangePercent": -39.07563, "earningsTimestamp": 1754483400, "earningsTimestampStart": 1754483400, "earningsTimestampEnd": 1754483400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -4.73, "epsForward": -5.85, "shortName": "iTeos Therapeutics, Inc.", "longName": "iTeos Therapeutics, Inc.", "epsCurrentYear": -3.84, "priceEpsCurrentYear": -2.643229, "fiftyDayAverageChange": 0.014699936, "fiftyDayAverageChangePercent": 0.0014503702, "twoHundredDayAverageChange": 1.8595247, "twoHundredDayAverageChangePercent": 0.22429653, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-07-24", "cryptoTradeable": false, "corporateActions": [{"header": "Delisting", "message": "ITOS is delisted effective Sep. 2, 2025", "meta": {"eventType": "DELISTING", "dateEpochMs": 1756785600000}}], "regularMarketTime": 1756411201, "exchange": "NGM", "messageBoardId": "finmb_663087242", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1595597400000, "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "iTeos Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-08-30"}]